Background: Myofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by the presence of myofascial trigger points (MTrPs) within the muscle fibers, leading to localized and referred pain. Conventional treatments for MPS, such as physical therapy, NSAIDs, and muscle relaxants, often provide limited relief. Botulinum toxin (BoNT), a neurotoxin that inhibits acetylcholine release at neuromuscular junctions, has emerged as a potential therapeutic agent for MPS. This study evaluates the efficacy of BoNT in the treatment of MPS, focusing on pain relief, trigger point resolution, and functional improvement. Objective: The primary objective of this study was to assess the efficacy of BoNT in reducing pain and improving functional outcomes in patients diagnosed with myofascial pain syndrome. Secondary objectives included evaluating the duration of pain relief, side effects, and impact on quality of life. Methods: A randomized controlled trial (RCT) was conducted at of Oral and Maxillofacial Surgery Department, Karachi Metropolitan University/Abbasi Shaheed Hospital with 150 patients diagnosed with MPS, divided into two groups: one receiving BoNT injections and the other receiving saline injections (placebo). The primary endpoint was the reduction in pain intensity measured on a Visual Analog Scale (VAS). Secondary outcomes included the number of MTrPs resolved, changes in the range of motion, and overall improvement in quality of life. Results: BoNT treatment significantly reduced pain intensity and the number of active MTrPs compared to the placebo group. On average, patients in the BoNT group reported a 50% reduction in pain intensity on the VAS, while the placebo group showed only a 15% reduction. Functional assessments showed improved range of motion and decreased disability in the BoNT group. Conclusion: Botulinum toxin is a promising treatment for myofascial pain syndrome, providing significant pain relief and functional improvement in patients with MPS. The findings support its inclusion as part of a multidisciplinary approach for managing MPS, although further studies are necessary to confirm long-term benefits and optimal dosing.